StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
CVSI

CV Sciences, Inc.

CVSI OTC Pharmaceutical Preparations EDGAR ↗
$0.02
+0.00 0.00%

Key statistics

from XBRL data in SEC filings
Market cap
$4.08M
Revenue (TTM)
$13.4M
Net income (TTM)
-$1.49M
EPS (TTM)
$-0.01
P/E ratio
Dividend yield
Free cash flow
-$516K
Cash
$309K
Total assets
$6.72M
Gross margin
49.8%
52-week range
$0.02 – $0.10

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Director or officer change; Shareholder vote results Jun 4, 2026 10-Q Quarter ended 2026-03-31 May 15, 2026 8-K Results of operations (earnings release); Regulation FD disclosure May 14, 2026 8-K Entered a material agreement; Took on a direct financial obligation Apr 10, 2026 10-K Fiscal year ended 2025-12-31 Mar 26, 2026 8-K Results of operations (earnings release); Regulation FD disclosure Mar 26, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Mar 10, 2026 10-Q Quarter ended 2025-09-30 Nov 13, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Nov 13, 2025 8-K Entered a material agreement Oct 10, 2025 8-K Entered a material agreement Sep 18, 2025 10-Q Quarter ended 2025-06-30 Aug 13, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Aug 13, 2025 8-K Shareholder vote results Jun 5, 2025 10-Q Quarter ended 2025-03-31 May 14, 2025 8-K Results of operations (earnings release); Regulation FD disclosure May 14, 2025 10-K Fiscal year ended 2024-12-31 Mar 27, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Mar 27, 2025 8-K Entered a material agreement Feb 20, 2025 8-K Other events Feb 19, 2025 8-K Terminated a material agreement Feb 11, 2025 8-K Other events Nov 25, 2024 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure Nov 21, 2024 10-Q Quarter ended 2024-09-30 Nov 14, 2024 8-K Results of operations (earnings release); Regulation FD disclosure Nov 14, 2024 10-Q Quarter ended 2024-06-30 Aug 13, 2024 8-K Results of operations (earnings release); Regulation FD disclosure Aug 13, 2024 8-K Entered a material agreement Jul 9, 2024 8-K Director or officer change Jun 25, 2024 8-K Shareholder vote results Jun 7, 2024 10-Q Quarter ended 2024-03-31 May 15, 2024 8-K Results of operations (earnings release); Regulation FD disclosure May 14, 2024 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure May 14, 2024 10-K Fiscal year ended 2023-12-31 Mar 29, 2024 8-K Results of operations (earnings release); Regulation FD disclosure Mar 28, 2024 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure Dec 12, 2023 10-Q Quarter ended 2023-09-30 Nov 14, 2023 8-K Results of operations (earnings release); Regulation FD disclosure Nov 14, 2023 10-Q Quarter ended 2023-06-30 Aug 14, 2023 8-K Results of operations (earnings release); Regulation FD disclosure Aug 14, 2023